Magrolimab is under clinical development by Gilead Sciences and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Magrolimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Magrolimab is under development for the treatment of Hodgkin lymphoma., previously untreated, relapsed or refractory acute myelocytic leukemia and myelodysplastic syndrome, solid tumor, relapsed/refractory multiple myeloma, recurrent head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, urethral cancer, metastatic urothelial cancer, metastatic small cell lung cancer and metastatic non-small cell lung cancer, ureter cancer, breast cancer, colorectal cancer, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, head and neck cancer, ovarian, AML, NHL, myelodysplastic syndrome, relapsed and refractory B-cell non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, triple negative breast cancer, indolent lymphoma, metastatic transitional (urothelial) tract cancer, bladder cancer, marginal zone or follicular lymphoma, malignant primary brain tumor, metastatic colorectal cancer and atherosclerosis. It is a humanized IgG4 subclass monoclonal antibody. The drug candidate is administered through intravenous route. It acts by targeting CD47.
It was also under development for cutaneous T-cell lymphoma.
Gilead Sciences overview
Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It is engaged in the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological and respiratory diseases, inflammation, liver diseases, cancer, and human immunodeficiency virus (HIV) infection. The company sells its products through subsidiaries and distributors in Europe, the Americas, Asia-Pacific, the Middle East and Africa. It has manufacturing facilities in Edmonton, Alberta, Canada; Foster City, San Dimas, Oceanside, California; and Cork, Ireland among others. The company has partnerships with universities, medical research institutions and global pharmaceutical leaders to develop new drugs. Gilead is headquartered in Foster City, California, the US.
For a complete picture of Magrolimab’s drug-specific PTSR and LoA scores, buy the report here.